A1's Top 5 Most Undervalued "U.S. Traded" Stocks, By Our DDDD: (Deep Dive Due Diligence)

A1 Financial's 5 top undervalued Nasdaq stocks in a chart

5 Stocks With Undeniable

Massive Upside Potential

Updated Feb 2nd, 2025

Let's begin by saying that any investment is risky. When you invest, only do so on your own due diligence. Anything can happen: When Covid news went worldwide in March 2020,

even the greats tumbled. Tesla fell to $103. Boeing fell to $113 pre-market. The Stock Market can be quite irrational.

At A1 we envision a day where stocks become valued by

share price as they should be.

Here are our current top 5 most undervalued stocks, after our deep dive of due diligence, that can relatively easily increase 3x to 10x or more, this week. We have filtered out all companies

with false high valuations that may place an offering (dilution) soon, or have internal red flags (such as we just found out from our China sources with HKD, our former #1, losing $100M Yuan on a failed November movie "A Cover-up" a.k.a. "The Man in the Wig".)):

#1 ACON Aclarion, Inc.

This one could be the largest riser in the entire SM over

the next few days. It has all the right things we consistently see for penny stocks that explode, shown below, and just revealed a breakthrough in spine treatment technology at a Spine Conference in Utah:

--Recent Reverse Split, its 2nd "Post RS" spike is expected any day now. Stocks with low floats have 2,3, even 4, like RNAZ just showed.

-Strong Q1+2+3 2024 Results 3 beats in a row!

-Tiny float. Standing at just 500K, this is a quite possible

"rocket" to the moon" candidate.

-High short float. Insanely "naked shorted", currently at

160.49 %. This high % combined with the tiny float make it

a top Short Squeeze candidate...30x the potential the famous

Game Stop had in 2020, due to the tiny, tiny float.

-Cash is solid: The company has 11.2 months of cash left based on quarterly cash burn of -$1.09M and estimated current cash of $4.1M.

-High Analysts' Price Targets: The top pros at Yahoo Financial

have a $345 long term pt. This is significant over what "invested" capital firms say, as they have no skin in the game, just evaluate fairly. It's also very realistic now that the breakthrough on spine treatment has been made.

-A Breakthrough Product: NOCISCAN is the first SaaS platform of its kind to offer a noninvasive method for physicians to assess lumbar spine discs, leveraging cloud technology to process and analyze MRI data for this purpose. Aclarion's focus on optimizing clinical treatments through advanced technology aligns with a growing trend in healthcare towards personalized medicine.

-Breaking News: Aclarion terminates ATM! As further dilution is not needed, Aclarion has terminated its At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC, ending its need to sell shares of its common stock through any new offering at this time.

Curr $6.60 Our =$57 (863% upside potential.)

#2 HOTH Hoth Therapeutics, Inc

In early January Hoth reported a "Breakthrough Cancer Treatment Success", and the stock soared 500% pre-market,

and ended up 215% . Sadly the Stock Market forgets these

things, that is where we come in --to remind you, the investor.

--Recently Compliant Hoth climbed above the $1 minimum and stayed there, thanks to the cancer news.

-Strong Q1+2+3 2024 Results 3 beats in a row!

-Tiny float. Standing at just 2.56M, this is a possible

"rocket" to the moon" candidate.

-High short float. Fluctuates up to as much as 1500%.

-Cash is solid: The company has 11.2 months of cash left based on quarterly cash burn of -$1.09M and estimated current cash of $4.1M.

-High Analysts' Price Targets: The top pros at Yahoo Financial

have a $5 long term pt. This is meager in our eyes-- with the stunning cancer breakthrough made.

Curr $1.25 Our PT =$8.50 (680% upside potential.)

#3 PALI Palisade Bio,INC

PALI is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that its abstract has been accepted for poster presentation at the Crohn’s & Colitis Congress being held February 6-8, 2025 in San Francisco, CA.

A recent offering (Dec) has set the company up well financially:

The company has 7.5 months of cash left based on quarterly cash burn of -$3.27M and estimated current cash of $8.2M.

-Small float. Standing at just 2.74M, this is a clear "rocket"

or "to the moon" candidate.

-High Analysts' Price Targets: The top pros at Yahoo Financial

have set a $8 to $45 long term pt.

Curr=$1.34 PT =$9 (671% upside potential.)

#4 LGMK LogicMark, Inc

This one could be the 4th largest riser in the entire SM over

the next few days. It has all the right things we consistently see for penny stocks that explode:

-Recent Reverse Split, its "Post RS" spike is well overdue!

-"Strong Q3 2024 Results Led by Double-Digit Growth in Year-Over-Year Sales and Gross Profit" was their recent ER PR.

-Small float. Standing at just 2.56M, this is a clear "rocket"

or "to the moon" candidate.

-High short float. Fluctuates up to as much as 1500%.

-Cash is solid: The company has 11.2 months of cash left based on quarterly cash burn of -$1.09M and estimated current cash of $4.1M.

-High Analysts' Price Targets: The top pros at Yahoo Financial

have a $4 long term pt. We agree exactly with YF.

Curr= $1.14--Our PT =$4 (350% upside potential.)

#5 ADTX Aditxt, Inc.

Positives:

-Dec 2023 This stock touched the equivalent of $380/sh.

SURE there has been dilution for acquisitions, but no where near -354,890% for Heaven's sake!

-ADTX is ambitious, they are attempting to acquire OTC company Apilli (APLIF).

-The company has 5.7 months of cash left based on quarterly cash burn of -$3.54M and estimated current cash of $6.7M.

-Their CEO STATED in a recent online interview, that much of the financing needed is already in place for the acquisition, their dilution for it has been completed, and is more than "priced in".

Negatives:

The RS value was at $4/sh, and it since has fallen to a

ridiculous .112

So much good, some bad. Quite confusing. We say this company is positioned quite well for long term growth, if the shareholders approve the MA and the financing goes well. The price is so

low, it is almost insane not to jump in and hold for the gold

of acquiring APLIF.

Curr=$.112 PT =$.35 (313% upside potential.)

Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Companies' current expectations and projections about future events that the Companies believe may affect its financial condition, results of operations, business strategy and financial needs. Shareholders can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" or other similar expressions. The Companies undertake no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations that arise after the date hereof, except as may be required by law. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions, and other factors discussed in the "Risk Factors" section of the registration statements on Form S-1 filed with the SEC and other filings with the SEC. Although the Companies believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Companies cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Companies; registration statements and other filings with the SEC. Additional factors are discussed in the Companies' filings with the SEC, which are available for review at www.sec.gov.